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Abstract  
High doses of antipsychotics have been associated with loss in cortical and total gray 
matter in schizophrenia. Though benzodiazepines are also commonly used in 
schizophrenia, previous imaging studies on have not taken this into account. In this study 
we examined the association between cumulative antipsychotic and benzodiazepine dose 
and brain volume change in schizophrenia cases with average illness duration over 10 
years at baseline. 38 individuals with schizophrenia and 69 controls from the Northern 
Finland Birth Cohort 1966 went through brain MRI at the ages of 34 and 43 years (nine-
year follow-up). Brain structures were delineated from MRIs using an automated volumetry 
system volBrain. Data on medication use was collected using medical records and 
interviews. The data were analyzed using linear regression model with intracranial volume 
and sex as covariates. Additionally, illness severity was also taken into account. Both 
antipsychotic and benzodiazepine dose during the scan interval associated statistically 
significantly to volumetric changes in subcortical structures. However, after adjusting for 
each other and the average PANSS total score, higher scan-interval antipsychotic dose 
associated only to volume increase in lateral ventricles (b=0.502, p=0.028) and higher 
benzodiazepine dose associated with volume decrease in the caudate nucleus (b=-0.422, 
p=0.029). To our knowledge, this is the first study to report associations between 
benzodiazepine dose and brain structural changes in schizophrenia. Further studies 
should focus on how these structural alterations correspond to cognition, functioning and 
other outcomes.  
 




1. Introduction  
 
Progressive changes in the brain structures of individuals with schizophrenia compared to 
healthy controls have been reported especially in frontal and temporal lobes, anterior 
cingulate, hippocampus, amygdala, thalamus and insula (Shepherd et al., 2012; Torres et 
al., 2013). The possible effects of antipsychotics on brain structure and functioning have 
been of interest during the last years (Andreasen et al., 2013; Ho et al., 2011; Radua et al., 
2012), and a meta-review concluded that previous comparisons between healthy controls 
and people with schizophrenia may be, at least partly, confounded by the effects of 
medication (Shepherd et al., 2012). However, in spite of several reviews and meta-
analyses (Fusar-Poli et al., 2013; Roiz-Santiáñez et al., 2015; Vita et al., 2015). On the 
association between antipsychotics and brain volume changes, the results are 
inconclusive with a need for further studies.  
The results from studies with rodents suggest that the effects of antipsychotics on the 
brain are evident also at later stages of the treatment (Terry et al., 2008, 2007a, 2007b; 
Terry and Mahadik 2007). However, many imaging studies in schizophrenia are made in 
the early phase of the illness, mostly during the first episode, when the possible long-term 
effects of medications may not yet be noticeable. Some studies focus on patients drawn 
from clinics serving chronic patients, where the patients might be on average sicker and 
therefore not representative of the great variety of different stages of illness found in entire 
population suffering from the disease. Clinical trials with strictly defined medication doses 
over years of follow-up are hard to conduct, and few include imaging measures in their 
protocol. Therefore the data from naturalistic settings is crucial when examining potential 
long-term effects and adverse effects of antipsychotic treatment (Wang et al., 2011). 
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Pharmacological treatment of schizophrenia is not limited to antipsychotic medication. 
Benzodiazepines are commonly used in schizophrenia as sedatives or anxiolytics and to 
reduce aggressiveness and ease agitation. In schizophrenia, benzodiazepine use has 
been associated with increased risk of mortality even after controlling for potential 
confounders (Fontanella et al., 2016) and, in general, benzodiazepine use has been 
associated with not only increased mortality (Tiihonen et al., 2016) but also cognitive 
impairment (Barker et al., 2005, 2004a, 2004b). Although the mechanism of these effects 
is unknown, adverse effects on brain health such as accelerated ageing, or decreases in 
brain volume, are possible candidate mechanisms that merit investigation. In the general 
population, approximately 3% use benzodiazepines over 6 months, which is defined as 
long-term treatment (Kurko et al., 2015). Recently chronic benzodiazepine use has been 
associated with decrease in brain plasticity in mice (Curto et al., 2016), but there are no 
modern structural imaging studies on benzodiazepine effects on the human brain. 
Previous studies have used computed tomography (CT) to study the effect of 
benzodiazepine use mainly on ventricular enlargement (Bust et al., 2000; Lader et al., 
1984; Moodley et al., 1993; Perera et al., 1987; Schmauss and Krieg 1987; Uhde and 
Keller 1987), but to our knowledge there are no previous MRI studies on benzodiazepine 
effects on brain structures in schizophrenia (or other conditions). 
In this study our aim was to analyze, in a population-based sample of schizophrenia cases 
with illness duration on average of 10 years at baseline, whether a nine-year scan-interval 
antipsychotic or benzodiazepine dose would have an effect on brain structural changes. 
This is the first longitudinal MRI study that we are aware of to investigate the effects of 
benzodiazepines on brain structure in schizophrenia and to examine the effects of 
antipsychotic medication on brain structure in schizophrenia whilst controlling for 
benzodiazepine use.  
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2. Experimental procedures 
Study sample   
This study is based on an unselected, general population birth cohort called The Northern 
Finland Birth Cohort 1966 (NFBC 1966). The Ethical Committee of the Northern 
Ostrobothnia Hospital District has approved the NFBC 1966 project and keeps its study 
design under continuous review. The sample collection is described in more detail in 
Veijola et al. (2014) and in Supplementary Methods. 
45 individuals with schizophrenia spectrum disorder and 77 controls participated in both 
studies when the participants were approximately 34 and 43 years old. At baseline the 
diagnoses were validated using Diagnostic and Statistical Manual of Mental Disorders 
Third Edition Revised (DSM-III-R) criteria (Isohanni et al., 1997; Moilanen et al., 2003) and 
confirmed at the follow-up using Structured Diagnostic Interview for DSM-III-R (SCID) 
(Spitzer et al.) and anamnestic information including individual hospital medical records. 
SCID was done also for controls. The specific diagnoses for the schizophrenia spectrum 
group were schizophrenia (N=40), schizophreniform disorder (N=1), schizoaffective 
disorder (N=3) and delusional disorder (N=1). Hereafter the term schizophrenia is used to 
refer to schizophrenia and other schizophrenia spectrum disorders. 
For seven participants with schizophrenia and seven controls MRI data were incomplete 
(scans missing or too poor quality at either time-point). One of the controls had had a 
psychotic episode during the follow-up period according to the Care Register for Health 
Care (CRHC) and was not included in the final study group. Therefore, the final 
schizophrenia group included 38 participants and the control group 69 participants. The 
sample collection is described in more detail in Supplement Figure 1 and in 
Supplementary Methods. 
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In schizophrenia group the participants did not differ statistically significantly from the non-
participants and are representative of the entire schizophrenia population in NFBC 1966 
regarding age, sex and educational level. In the control group, the participants’ level of 
education was higher than of the non-participants (Veijola et al., 2014).  
Data on medication  
Life-time psychiatric medication use was collected using all available medical records 
(hospital and out-patient care case notes), an interview conducted during the field study at 
both time points, and the register of the Finnish Social Insurance Institution on 
psychoactive medications consumed during 1997 (Husa et al., 2014; Veijola et al., 2014). 
The medical records were acquired on the basis of information concerning the subjects’ 
treatment facilities, which we received from the CRHC. If the subject had no information in 
the CRHC, we requested medical records from the outpatient facilities of the subjects’ area 
of residence. Participants in this study had given their permission to collect medical 
records by signing the written informed consent. We had permission for collecting the data 
from the Ministry of Social Affairs and Health.  
All medical records were reviewed to record the name of the drug, dose and time period 
the medication had been used. Drugs were categorized by using the Anatomical 
Therapeutic Chemical (ATC) classification system (WHO 2010). Antipsychotics included 
classes N05A (antipsychotics) and Pertriptyl (N06CA01 combination medicine including 
perphenazine). Benzodiazepines included ATC classes N05BA (anxiolytics, 
benzodiazepine derivatives), N05CD (hypnotics and sedatives, benzodiazepine 
derivatives), and N05CF (hypnotics and sedatives, benzodiazepine-related drugs). For 
antipsychotic medication, the information was used to calculate the cumulative doses of 
lifetime and interscan interval antipsychotic doses expressed as dose-years of a daily dose 
of 100 mg chlorpromazine (CPZy) using several sources, see Moilanen et al. (2015) for 
 7 
details. For benzodiazepines, the information was used to calculate the defined daily 
doses (DDD) (Nykänen et al., 2016; Rissanen et al., 2015), these were then expressed as 
dose-years. One DDD dose year (DDDy) is equivalent to the amount of medication, which 
a person would use if the daily dose was 1 DDD and the duration of treatment would be 
one year. 
Covariates and background variables 
Onset age of the illness was ascertained from medical records and it was defined as the 
age of first evident psychotic symptoms. Clinical symptoms in participants with 
schizophrenia at baseline and follow-up were examined using the Positive and Negative 
Syndrome Scale (PANSS) (Kay et al., 1987). In the baseline study, the PANSS was 
measured based on the SCID I -interview and general psychiatric interview, while in the 
follow-up study PANSS was defined using a specific PANSS interview. The number of 
hospital days during the follow-up was collected from the CRHC. Remission was assessed 
using the Andreasen symptomatic criteria (Andreasen et al., 2005), but the symptoms 
were only required not to be present at the time of the assessment, and no duration criteria 
was used since PANSS was done only once at baseline and follow-up. 
MRI methods  
The participants were scanned with the same 1.5 T GE Signa scanner (General Electric, 
Milwaukee, Wisconsin) at both baseline and follow-up at the Oulu University Hospital. At 
baseline T1-weighted high-resolution three dimensional spoiled gradient echo (3D SPGR) 
images were acquired in the coronal plane covering the whole brain (slice thickness 1.5 
mm; in-plane resolution matrix size 256x256; voxel size 1.5 mm x 1 mm x 1 mm; repetition 
time 35 ms; echo time 5 ms; flip angle = 35). Prior to the follow-up imaging the scanner 
was up-graded into HDxt with a new gradient system and parallel image data acquisition 
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with an 8 channel receiving coil. At follow-up, the T1 weighted images were acquired with 
a 3D fast spoiled gradient echo (FSPGR) sequence (slice thickness = 1 mm; in-plane 
resolution matrix size 256x256; voxel size 1 mm3; repetition time 12.576 ms; echo time 5.3 
ms; flip angle =20).  
MRI data processing 
To extract the brain tissue volumes from the MRI images we used an online automated 
MRI brain volumetry system volBrain (http://volbrain.upv.es/) (Manjón and Coupe 2016). 
VolBrain segments the MRI into 15 different brain tissue classes or structures (white 
matter (WM), gray matter (GM), cerebrospinal fluid (CSF), brain (WM+GM), intracranial 
cavity, cerebrum, cerebellum, brainstem, lateral ventricles, caudate, putamen, thalamus, 
globus pallidus, hippocampus, amygdala, accumbens) separated in right and left if 
applicable. Details on the image processing pipeline are provided in Supplementary 
Methods. In this study we focused mainly on subcortical structures. 
Since there are many concerns regarding the methodology and replicability of measures in 
longitudinal MRI studies, and as we had a scanner update during the follow-up, we also 
performed a calibration scan inviting 15 controls to be scanned with both used protocols 
during the same day to assess the possible effect of the scanner update on our 
measurements. With the help of these calibration-scans, we measured the inter-scan 
reliability rates for each extracted brain structure volume and excluded the structures with 
single measures intraclass correlation poorer than 0.90. For more information on the 
calibration scan and reliability measures, see Supplementary Methods and Supplement 
Table 1. 
We calculated the annual change of each studied brain region using the total change 
during the follow-up and the length of follow-up for each individual.  
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Statistical analyses 
The brain structural MRI changes were examined in 10 different measures based on the 
interest in subcortical structures and our inter-scan reliability measures. These areas were: 
total brain, total gray matter (GM), cerebrum, cerebral GM, lateral ventricles, caudate 
nucleus, putamen, thalamus, hippocampus, and nucleus accumbens. We analyzed 
differences between subjects with schizophrenia and non-psychotic controls and 
associations between medication doses and brain areas in the schizophrenia group. We 
used sex and intracranial volume (ICV) at baseline as covariates in all analyses. 
We analyzed the association between our two medication variables (cumulative 
antipsychotic dose in dose years during the scan interval and cumulative benzodiazepine 
dose in dose years during the scan interval) and structural MRI changes using a linear 
regression analysis. All analyses were adjusted for sex and baseline ICV. We ran 
correlations between different covariates and medication variables, and between 
covariates and brain structural changes to choose potential confounding factors for the 
analyses. These confounding factors were onset age, average PANSS score between the 
two time points, and cumulative number of hospital days during the follow-up. In addition, 
we added benzodiazepine use as a covariate in antipsychotic effect analyses and vice 
versa.  
We applied a logarithmic transformation to medication data and the number of hospital 
days during the follow-up and used them as continuous variables in analyses.  
The analyses were performed using IBM SPSS Statistics version 23 using p<0.05 as a 
limit for statistical significance.  
3. Results 
Characteristics of the Sample 
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The characteristics of the schizophrenia and control samples are described in Table 1. The 
clinical characteristics of the schizophrenia group are described in Table 2. In 
schizophrenia group the number of males was 21 (54%), age at baseline was on average 
33.7 years and the length of follow-up was 9.1 years. At baseline 13 (34 %) subjects were 
in remission and at follow-up 12 (32 %). Fourteen (37%) subjects were on disability 
pension at baseline and the average PANSS score between the two time points was 61.4 
(SD 20.7). 
Schizophrenia cases showed statistically significant decrease in the volumes of total brain 
(t=-2.27, p=0.025), cerebrum (t=-0.38, p=0.019), caudate nucleus (t=-4.05, p<0.0001), 
thalamus (t=-0.14, p=0.035) and hippocampus (t=-0.023, p=0.028) when compared to 
controls. All results on case control differences are presented in Supplement Table 2 and 
the average volume change in cases and controls is presented in Supplement Table 3. 
Medication use characteristics 
Medication use characteristics of the schizophrenia group are described in Table 3. Before 
baseline 37 (97%) schizophrenia subjects had been medicated with antipsychotics. All of 
them had used typical antipsychotics and 20 (53%) had used atypical antipsychotics. The 
mean cumulative dose of antipsychotics by baseline was 27.6 (SD 34.9) CPZy.  
During the follow-up 34 (90%) subjects used antipsychotics. Five subjects (13%) used only 
typical antipsychotics and six subjects (15%) used only atypical antipsychotics. Twenty-
three (61%) subjects used both typical and atypical antipsychotics during the follow-up. 
The mean dose of antipsychotics during the follow-up for all medicated subjects was 28.5 
(SD 24.8) CPZy, for subjects using only typical antipsychotics 7.7 (SD 9.3) CPZy, and for 
subjects using only atypical antipsychotics 19.0 (SD 18.7) CPZy. 
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Before baseline 36 (95%) subjects had used benzodiazepines. Five (14%) subjects had 
used benzodiazepines only irregularly (prescribed to be taken only when needed). The 
mean cumulative dose of benzodiazepines by baseline was 3.6 DDDy (SD 4.3 DDDy). 
During the follow-up 30 (79%) subjects used benzodiazepines. Ten (33 %) subjects used 
benzodiazepines only irregularly during the follow-up. The mean dose during the follow-up 
was 6.7 DDDy (SD 8.2 DDDy). 
Association between cumulative antipsychotic dose during the follow-up and brain 
changes 
Higher scan interval antipsychotic dose associated with increased lateral ventricle volumes 
(b=0.46, p=0.012) and decrease in volumes of total GM (b=-0.38, p=0.012), cerebral GM 
(b=-0.39, p=0.012), thalamus (b=-0.34, p=0.030), hippocampus (b=-0.34, p=0.040) and 
nucleus accumbens (b=-0.38, p=0.018). After adjusting antipsychotic effects with 
benzodiazepine use and PANSS average score, only the finding regarding lateral 
ventricles remained statistically significant (b=0.50, p=0.028). Even when hospital days 
during the follow-up was added to the model, the association still remained (b=0.487, 
p=0.035). 
On the areas where PANSS average score during the follow-up was statistically 
significantly associated with brain structure volume changes (total GM, cerebral GM and 
nucleus accumbens), the size of the effect was roughly the same as the association of 
antipsychotic dose on those brain areas. The effect of onset age was also roughly the 
same as the effect of antipsychotic dose on the same areas. All results regarding all 
covariates and brain volumes are presented in Table 4. Tables 5.1 and 5.2 present the 
results of antipsychotic and benzodiazepine dose effects in adjusted analyses. 
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Association between cumulative benzodiazepine dose during the follow-up and 
brain changes 
Higher scan interval benzodiazepine dose associated with increase in lateral ventricles 
(b=0.35, p=0.037) and decrease in total brain (b=-0.35, p=0.037), cerebrum (b=-0.32, 
p=0.048), caudate nucleus (b=-0.49, p=0.002), thalamus (b=-0.36, p=0.033) and nucleus 
accumbens (b=-0.40, p=0.018). After adjusting for antipsychotic dose and PANSS average 
score only the finding regarding caudate nucleus remained (b=-0.42, p=0.029).   
4. Discussion  
Main results 
In this study, schizophrenia cases showed more increase in lateral ventricles over time 
than non-psychotic controls and more decrease in the volumes of total brain, caudate 
nucleus and hippocampus. In subjects with schizophrenia, antipsychotic medication dose 
during the follow-up related to increase in lateral ventricles when taking into account illness 
severity measures and benzodiazepine dose. Benzodiazepine use associated with 
caudate volume reduction after adjusting for average PANSS score and antipsychotic 
dose.  
Antipsychotic use and brain volume change 
In the NFBC 1966 we have found that in schizophrenia, higher amount of antipsychotic 
medication over the 9-year follow-up predicted larger total brain volume loss (Veijola et al., 
2014). Consistent with those results, here, using a different image analysis method, we 
noted associations between antipsychotic medication exposure and decrease in total grey 
matter (with a marginal effects on total brain volume). These effects were attenuated when 
we controlled for potential confounding factors including benzodiazepine use, which we 
and others did not control for in previous studies.  However, the association we observed 
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here between antipsychotic medication exposure and lateral ventricular change was robust 
to controlling for illness severity and benzodiazepine use. In our previous studies in this 
sample using the FSL tool SIENA to examine movement over time (atrophy) at the brain 
edge, we noted an association between antipsychotic medication use and lateral 
ventricular volume increase (Vejola et al., 2014), and with periventricular brain volume 
reductions at the fourth ventricular edge (Guo et al., 2015). When viewing these studies 
using different methods together, it appears in our sample that there is a consistent 
association between antipsychotic medication exposure and ventricular volume change. 
However, we recognize that not all other studies have noted similar effects (Ho et al., 
2011; Saijo et al., 2001; Puri et al., 2001).   
We have also studied cognition in this sample in relation to medication. Higher dose-years 
of antipsychotics associated with decline in verbal learning and memory between ages 34 
and 43 years (Husa et al., 2014), and high lifetime dose and antipsychotic polypharmacy 
associated also with poorer outcomes in schizophrenia at the age of 43 years (Moilanen et 
al., 2015). These results are consistent with the possibility that long-term antipsychotic 
medication has some adverse effects on the brain, although it remains possible that 
residual confounding may be responsible for these associations. For example, although 
we adjust for illness severity in our sample, there is no gold standard way to measure 
illness severity. Patients with the most severe illness may be the ones who are prescribed 
the most medication by doctors attempting to regain symptom control, but it may be that a 
more severe disease process results, through unknown mechanisms unrelated to 
medication, in the most cognitive decline and the most progressive brain atrophy. 
The potential antipsychotic effect on brain structures in schizophrenia was suggested 
already in the 1970’s by Marsden (Marsden, 1976) in response to the report on lateral 
ventricle increase in schizophrenia by Johnstone et al. (1976).  Since then the issue has 
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raised again on the 2000’s as second-generation antipsychotics have been studied 
excessively and been compared with traditional first-generation antipsychotics (e.g. 
Crespo-Facorro et al., 2008; Lieberman et al., 2005; Mamah et al., 2012; Roiz-Santiáñez 
et al., 2012). Animal studies have examined different antipsychotic agents and treatments, 
and the results suggest that antipsychotics may have effects on brain structures even 
when illness related confounding factors present in human studies are excluded (Dorph-
Petersen et al., 2005; Vernon et al., 2014, 2011). 
The possible mechanism behind antipsychotic-related structural brain changes is not clear. 
In striatal areas antipsychotics may increase striatal metabolism as a consequence of 
neurons trying to overcome antipsychotic induced D2 blockade and therefore lead to 
increased volumes (Buchsbaum et al., 1992). In literature this has been associated 
especially to typical antipsychotic use, whereas some studies have found atypical 
antipsychotics to even reverse the effect after switching (Lang et al., 2004; Scheepers et 
al., 2001). However, a systematic review on antipsychotic monotherapy effects in basal 
ganglia reported that no studies found typical antipsychotics to induce basal ganglia 
volume increases, but atypical antipsychotics have been associated to both increases and 
decreases (Ebdrup et al., 2013). On cortical volumes, wide-spread reductions in 
antipsychotic exposed monkeys (Dorph-Petersen et al., 2005) were traced to result from 
lower astrocyte number that both haloperidol and olanzapine exposure associated with 
(Konopaske et al., 2007). On the contrary, antipsychotic induced decrease in volume and 
thickness of anterior cingulate cortex in rats was not associated to decrease in astrocyte 
number but instead an increase in cell number (Vernon et al., 2014). 
Benzodiazepine use and brain volume change 
Though the association of antipsychotic medication on structural changes in the brain has 
gained a lot of attention in the previous years, the effects of benzodiazepines have not 
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been taken into account. In studies with over 2 year follow-ups looking at associations 
between antipsychotics and brain MRI findings in schizophrenia only one used 
benzodiazepine use as an exclusion criteria (Molina et al., 2005), 5 reported in their 
methods that subjects used also benzodiazepines (Takahashi et al., 2012, 2011a, 2011b, 
2010, 2009) and only one study briefly discussed the potential confounding effect of 
benzodiazepine use and need for further research on how benzodiazepines may affect 
brain structures (Takahashi et al., 2010). 
The results of earlier CT studies on benzodiazepine effects on brain structures are 
inconsistent, though it has to be noted, that the topic has been studied very little. The most 
recent studies on benzodiazepine effects on brain structures detected by CT concluded 
that long-term benzodiazepine use does not result in brain abnormalities (Busto et al., 
2000; Lader et al., 1984; Moodley et al., 1993; Perera et al., 1987). However, two studies 
have found that benzodiazepines associate to ventricle-to-brain ratio (Schmauss and Krieg 
1987; Uhde and Kellner 1987) and the other even suggested a dose-dependent effect 
(Schmauss and Krieg 1987). Since benzodiazepine use has been associated with decline 
in cognition (Barker et al., 2004a, 2004b) and decreased structural plasticity in pyramidal 
neurons in mice (Curto et al., 2016), there is a need for understanding the molecular 
mechanisms behind benzodiazepine effects on the brain.  
Knowing the potential effects and adverse effects benzodiazepines may have on brain 
structure and functioning is essential in schizophrenia, because the prevalence of 
benzodiazepine use varies from 15% to even 91% (Mundt et al., 2012; Vares et al., 2011; 
Waterreus et al. 2012). In the Northern Finland Birth Cohort 1966 (NFBC 1966), 42% of 
individuals with schizophrenia used benzodiazepines at the age of 43 (Nykänen et al. 
2016), and in our study, 95% of patients had used benzodiazepines prior to study 
commencement, with 79% using them in the inter-scan interval. In addition, 
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benzodiazepines are commonly used in general population: approximately 3% use 
benzodiazepines over 6 months and in some populations the number is even higher 
(Kurko et al., 2015). The fact that these medications are so widely used underlines the 
importance of studying their long-term effects carefully. 
Methodological discussion 
This study partly demonstrates the importance of using adequate covariates when 
studying variables that are sensitive to confounding factors. Taking illness related factors 
into account in this study was challenging, as the used variables correlated with each other 
(see Supplement Table 4). In previous studies illness severity and potential confounding 
medication have not been taken into account comprehensively. Because antipsychotic 
medication is the key treatment in schizophrenia and other psychoses, it is highly 
important to take possible confounding factors into account when studying potentially 
harmful effects of these medications. Still, only a few previous studies with long-term 
follow-ups have adjusted their analyses with illness severity measures when analyzing 
antipsychotic effects on brain structures (Andreasen et al., 2013; Guo et al., 2015; Ho et 
al., 2011; Veijola et al., 2014).  
Imaging studies are often sensitive to confounding effects due to various reasons. To 
exclude natural variation in brain volumes between two time point images, the protocol 
before each scan should be as strictly the same as possible, for example the diet and fluid 
intake should be comparable. The scanner should be the same, it should not be updated 
and phantoms should be imaged frequently for maximal quality. Issues rising from these 
factors potentially confound the results of imaging studies and though they are well-known, 
they are hard to rule out when conducting longitudinal studies. 
Strengths and limitations 
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One strength of this study is the comprehensive, thoroughly collected medication data. To 
our knowledge, there is no such data on longitudinal use of both antipsychotics and 
benzodiazepines anywhere in the world. Our data has been collected using several 
sources: by interviewing the person themselves, interviewing the care takers and by 
scrutinizing all available medical records and collecting all available information on 
medication adherence, prescribed doses and duration of treatments. 
Another strength is the rare naturalistic setting that is tailor-made for studying long-term 
associations, effects and adverse effects of medications (Wang et al., 2011). Naturalistic 
settings may provide novel information and perspective in contrast to clinical studies that 
are often made with determined objectives and in more strictly defined study populations. 
A limitation in our study is the sample size. Though there were 101 identified 
schizophrenia cases in the NFBC 1966 in the beginning of this study, only 73 of them 
participated at baseline and 45 at follow-up. Possibly partly because of active home-
recruitment in our study, the participants did not differ from the non-participants in terms of 
age, sex or educational level (Veijola et al., 2014). Still, we cannot be certain this sample 
represents our study population extensively in all measured domains. 
Sample size limits the power to find associations and due to several analyses some 
associations may be due to chance. Small sample size also affected our decision not to 
correct for multiple comparisons when analyzing different brain areas, since the size of 
brain structures are connected to each other and a conservative correction method (e.g. 
Bonferroni) would probably over-correct the results. Given these facts, the results of this 
study need to be interpreted cautiously and they need to be replicated especially regarding 
the findings on benzodiazepines. 
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Another limitation is the uncertainty regarding the MRI methods used. Though we tried to 
overcome the possible interference by using test-retest measures, we cannot be sure our 
findings are a result of true differences between the studied populations. In any case, we 
emphasize that the results of this study are only observed differences between the MRI 
measures at two different time points and we do not suggest a causal effect. 
Conclusions 
Cumulative antipsychotic dose associates to ventricular enlargement in schizophrenia 
even after controlling for benzodiazepine use and illness related factors. Nevertheless it 
cannot be concluded that antipsychotics themselves cause the ventricular enlargement 
found in this study, but rather the use of antipsychotics may be a marker for a factor we 
are unable to identify, which contributes to ventricular enlargement. 
This study assesses the association between benzodiazepine dose and structural brain 
changes for the first time in schizophrenia and though it was not possible to detect 
benzodiazepine associated changes with a limited sample size, our results suggest, that in 
future, studies focusing on antipsychotic effects should take benzodiazepine use into 
account because of its potential to confound the results.  
There is a need for understanding the mechanisms behind antipsychotic and 
benzodiazepine related structural and functional changes in the brain. Further studies 
should also focus on how medication related structural alterations correspond to cognition 
and functioning.  
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